The Indiana serotype of vesicular stomatitis virus (VSVIND), but not the New Jersey serotype (VSVNJ), has been widely used as a gene expression vector. In terms of prime–boost-based vaccine strategies, it would be desirable to use two different VSV serotypes to avoid immunity against the priming viral vector. Here, we report that we have applied the VSVNJ vector system for expression of the env gene of human immunodeficiency virus type 1 (HIV-1). The HIV-1 env gene was inserted into the VSVNJ vector system at two different sites: between the P and M genes (NP-gp160-MGL) and between the G and L genes (NPMG-gp160-L). The HIV-1 env gene product, gp160, was efficiently expressed and processed in cells infected with either of these two recombinant VSV–HIV-1gp160 viruses. In this study, we have investigated the applicability of the VSVNJ vector system for foreign gene expression.
BlackB. L.,
RhodesR. B.,
McKenzieM.,
LylesD. S.1993; The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J Virol 67:4814–4821
EganM. A.,
CarruthL. M.,
RowellJ. F.,
YuX.,
SilicianoR. F.1996; Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55 gag precursor protein. J Virol 70:6547–6556
EganM. A.,
ChongS. Y.,
RoseN. F.,
MegatiS.,
LopezK. J.,
SchadeckE. B.,
JohnsonJ. E.,
MasoodA.,
PiacenteP.other authors2004; Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20:989–1004[CrossRef]
EllisR. J.,
HemmingsenS. M.1989; Molecular chaperones: proteins essential for the biogenesis of some macromolecular structures. Trends Biochem Sci 14:339–342[CrossRef]
FlanaganE. B.,
BallL. A.,
WertzG. W.2000; Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. J Virol 74:7895–7902[CrossRef]
JohnsonK. M.,
VogelJ. E.,
PeraltaP. H.1966; Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg 15:244–246
KapadiaS. U.,
RoseJ. K.,
LamirandeE.,
VogelL.,
SubbaraoK.,
RobertsA.2005; Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340:174–182[CrossRef]
KelleyJ. M.,
EmersonS. U.,
WagnerR. R.1972; The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. J Virol 10:1231–1235
KimG. N.,
KangC. Y.2007; Matrix protein of VSV New Jersey serotype containing methionine to arginine substitutions at positions 48 and 51 allows near-normal host cell gene expression. Virology 357:41–53[CrossRef]
LaBrancheC. C.,
SauterM. M.,
HaggartyB. S.,
VanceP. J.,
RomanoJ.,
HartT. K.,
BugelskiP. J.,
MarshM.,
HoxieJ. A.1995; A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J Virol 69:5217–5227
LawsonN. D.,
StillmanE. A.,
WhittM. A.,
RoseJ. K.1995; Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92:4477–4481[CrossRef]
McGettiganJ. P.,
NaperK.,
OrensteinJ.,
KoserM.,
McKennaP. M.,
SchnellM. J.2003; Functional human immunodeficiency virus type 1 (HIV-1) Gag–Pol or HIV-1 Gag–Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol 77:10889–10899[CrossRef]
McKennaP. M.,
McGettiganJ. P.,
PomerantzR. J.,
DietzscholdB.,
SchnellM. J.2003; Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 1:229–237[CrossRef]
MelkiR.,
GaudinY.,
BlondelD.1994; Interaction between tubulin and the viral matrix protein of vesicular stomatitis virus: possible implications in the viral cytopathic effect. Virology 202:339–347[CrossRef]
RoseN. F.,
RobertsA.,
BuonocoreL.,
RoseJ. K.2000; Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74:10903–10910[CrossRef]
RoseN. F.,
MarxP. A.,
LuckayA.,
NixonD. F.,
MorettoW. J.,
DonahoeS. M.,
MontefioriD.,
RobertsA.,
BuonocoreL.,
RoseJ. K.2001; An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539–549[CrossRef]
RowellJ. F.,
StanhopeP. E.,
SilicianoR. F.1995; Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol 155:473–488
SchneiderJ.,
KaadenO.,
CopelandT. D.,
OroszlanS.,
HunsmannG.1986; Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol 67:2533–2538[CrossRef]
SchnellM. J.,
BuonocoreL.,
KretzschmarE.,
JohnsonE.,
RoseJ. K.1996a; Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 93:11359–11365[CrossRef]
SchnellM. J.,
BuonocoreL.,
WhittM. A.,
RoseJ. K.1996b; The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70:2318–2323
SteinB. S.,
EnglemanE. G.1990; Intracellular processing of the gp160 HIV-1 envelope precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex. J Biol Chem 265:2640–2649
WertzG. W.,
PerepelitsaV. P.,
BallL. A.1998; Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci U S A 95:3501–3506[CrossRef]
WertzG. W.,
MoudyR.,
BallL. A.2002; Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J Virol 76:7642–7650[CrossRef]